Document Detail

Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis.
MedLine Citation:
PMID:  23323577     Owner:  NLM     Status:  In-Data-Review    
Purpose: To establish evidence-based recommendations regarding the use of anti-Tumor Necrosis Factor alpha (TNF-α) agents for managing uveitis patients. Methods: Medline was searched via OVID (1950 - October Week 3, 2011) using a Cochrane highly sensitive search (phases 1 and 2). Additional literature searches were also conducted incuding the following databases: the Cochrane, LILACS and the TRIP Database. Results: A total of 54 studies met all of the inclusion criteria and were included in this review. A different level of recommendation and evidence is assigned to each anti-TNF-α agent. The overall rate of reported side effects with anti-TNF-α agents for the treatment of uvetis which required discontinuation of therapy was 2.2% (26/1147 patients). Conclusion: Based on the evidence gathered, infliximab and adalimumab seem to be effective in the management of immune-mediated uveitis. Further randomized studies evaluating the efficacy of these agents are warranted. It is the most common cause of inflammatory eye disease, with an estimated prevalence of 115 cases per 100,000 persons.( 1 ) Endogenous or associated with a systemic disease, noninfectious uveitis accounts for approximately 75% of total cases comprising of a heterogeneous group of inflammatory conditions responsible for about 10% of legal blindness in developed nations.( 1 , 2 ) Endogenous uveitides are thought to have an autoimmune component mediated by T lymphocytes specific to intraocular antigens that have failed to successfully pass basic processes designed to maintain self-tolerance.
Miguel Cordero-Coma; Taygan Yilmaz; Sumru Onal
Related Documents :
9480697 - Monogyny and regulation of worker mating in the queenless ant dinoponera quadriceps
24227137 - Antibody responses in mice to particles formed from adsorption of a murine monoclonal a...
9934677 - Protease-resistant prion protein produced in vitro lacks detectable infectivity.
21508117 - Infectious microorganisms in mice (mus musculus) purchased from commercial pet shops in...
18160647 - Impaired migration in the rostral migratory stream but spared olfactory function after ...
10438907 - Strain variation in autoimmunity: attempted tolerization of da rats results in the indu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Ocular immunology and inflammation     Volume:  21     ISSN:  1744-5078     ISO Abbreviation:  Ocul. Immunol. Inflamm.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9312169     Medline TA:  Ocul Immunol Inflamm     Country:  England    
Other Details:
Languages:  eng     Pagination:  12-20     Citation Subset:  IM    
Department of Ophthalmology, Hospital Universitario de León , Leon , Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Toxic-inflammatory effects of prostoglandin analogs on the ocular surface.
Next Document:  Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis.